


PHARMACEUTICAL 2018

ALIMERA SCIENCES INC Rank 130 of 349







PHARMACEUTICAL 2018

ALIMERA SCIENCES INC Rank 130 of 349



The relative strengths and weaknesses of ALIMERA SCIENCES INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALIMERA SCIENCES INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 274% points. The greatest weakness of ALIMERA SCIENCES INC is the variable Other Expenses, reducing the Economic Capital Ratio by 267% points.

The company's Economic Capital Ratio, given in the ranking table, is -95%, being 182% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	39,322
Cost of Goods Sold	0
Intangible Assets	18,664
Liabilities, Current	9,671
Liabilities, Non-Current	0
Other Assets	528
Other Compr. Net Income	451
Other Expenses	32,223
Other Liabilities	0
Other Net Income	193
Property and Equipment	1,410
Research and Development	12,844
Revenues	35,912
Selling, General and Administrative Expense	13,039

Output Variable	Value in 1000 USD
Assets	59,924
Liabilities	9,671
Expenses	58,106
Stockholders Equity	50,253
Net Income	-22,001
Comprehensive Net Income	-21,776
Economic Capital Ratio	-95%

